General
Preferred name
toremifene
Synonyms
TOREMIFENE CITRATE ()
Toremifene (Citrate) ()
Z-Toremifene (citrate) ()
NK 622 ()
FC-1157a ()
Z-Toremifene ()
NK 622 (free base) ()
FC-1157a (free base) ()
NSC 613680,NK 622 Citrate ()
Toremifene Citrate (NK 622) ()
Fareston ()
NSC-613680 ()
Chlortamoxifen ()
GTX-006 ()
J33.157K ()
Acapodene ()
Farestone ()
Toremiphene ()
Toremifeno ()
Toremifene-d6 ()
P&D ID
PD009971
CAS
89778-26-7
275360-73-1
89778-27-8
Tags
available
drug
Approved by
FDA
First approval
1997
1996
Drug indication
Breast cancer
breast neoplasm
Coronavirus Disease 2019 (COVID-19)
Neoplasm
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 ¦ÌM and 2.6 ¦ÌM, respectively[1][2].
DESCRIPTION Toremifene is an orally active, selective estrogen receptor modulator (SERM). (GtoPdb)
DESCRIPTION Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 ¦ÌM and 2.6 ¦ÌM, respectively[1][2].
Cell lines
2
Organisms
6
Compound Sets
26
Cayman Chemical Bioactives
20854
30728
ChEMBL Approved Drugs
CHEMBL1200675
CHEMBL1655
ChEMBL Drugs
CHEMBL1200675
CHEMBL1655
Concise Guide to Pharmacology 2017/18
4325
Concise Guide to Pharmacology 2019/20
4325
Concise Guide to Pharmacology 2021/22
4325
Concise Guide to Pharmacology 2023/24
4325
Drug Repurposing Hub
DrugBank
DB00539
DrugBank Approved Drugs
DB00539
DrugCentral
2709
DrugCentral Approved Drugs
2709
DrugMAP
DMKD6GA
DMQYUWG
DrugMAP Approved Drugs
DMQYUWG
Guide to Pharmacology
4325
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1655
Mcule NIBR MoA Box Subset
MCULE-6965711017
MedChem Express Bioactive Compound Library
HY-B0005
HY-B0005A
NCATS Inxight Approved Drugs
7NFE54O27T
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Toremifene-Citrate(Fareston)
The Spectrum Collection
External IDs
56
Properties
(calculated by RDKit )
Molecular Weight
405.19
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
0
Rotatable Bonds
9
Ring Count
3
Aromatic Ring Count
3
cLogP
6.22
TPSA
12.47
Fraction CSP3
0.23
Chiral centers
0.0
Largest ring
6.0
QED
0.31
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
virtual
MOA
Selective Estrogen Receptor Modulators (SERM)
estrogen receptor antagonist, selective estrogen receptor modulator (SERM)
Indication
breast cancer
Target
ESR1
Apoptosis
Estrogen Receptor/ERR
Estrogen/progestogen Receptor
Therapeutic Class
Anticancer Agents
Antiviral Agents
Pathway
Vitamin D Related/Nuclear Receptor
Source data